中国感染控制杂志2023，Vol.22Issue(12)：1411-1424,14.DOI:10.12138/j.issn.1671-9638.20234364
免疫缺陷人群新型冠状病毒感染诊治策略中国专家共识(2023.V2版)
Chinese expert consensus on diagnosis and treatment strategies for SARS-CoV-2 infection in immunocompromised populations(2023 edition-2)
摘要
Abstract
Since the end of 2019,severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)infection has swept the world,bringing great harm to human society and significantly increasing the health burden.Due to stron-ger infectivity,faster transmission,and higher reinfection rate of the Omicron variant,it has now replaced the Delta variant as the main epidemic strain for both imported and local outbreaks in China.Chinese Diagnosis and treatment protocol for SARS-CoV-2 infection(10th trial version)emphasizes"strengthening the protection of key popula-tions,"which includes the increasing number of immunocompromised population.These people have a high inci-dence of severe diseases and a high fatality rate after infected with SARS-CoV-2,and belong to the high-risk popula-tions of severe or critical diseases.Moreover,due to underlying diseases,these people take immunosuppressants and other related drugs chronically.The interactions between anti-SARS-CoV-2 infection treatment drugs and origi-nal drugs are complicated,thus bring significant challenges to the treatment after the SARS-CoV-2 infection.Cur-rently,there is a lack of guidelines or consensus on the diagnosis and treatment of SARS-CoV-2 infection among im-munocompromised population.Therefore,the Guangzhou Institute of Respiratory Health and National Center for Respiratory Medicine organized experts from multiple disciplines(respiratory and critical care medicine,organ transplantation,rheumatology and immunology,hematology,infection,critical care medicine,etc.)in China.Af-ter multiple rounds of discussions,13 items of recommendations are made as the reference for peers based on evi-dence-based medical evidence,so as to provide a theoretical and practical reference for the diagnosis and treatment strategies of this population.关键词
新型冠状病毒/免疫缺陷人群/肺炎/小分子药物Key words
SARS-CoV-2/immunocompromised population/pneumonia/small molecule drug分类
医药卫生引用本文复制引用
巨春蓉,薛武军,卢洪洲,黎毅敏,俞云松,王梅英,袁静,徐永昊,许芝彬,徐培航,赖逾鹏,陈莉延,李时悦..免疫缺陷人群新型冠状病毒感染诊治策略中国专家共识(2023.V2版)[J].中国感染控制杂志,2023,22(12):1411-1424,14.基金项目
国家重点研发计划公共安全风险防控与应急技术装备专项-新冠应急项目(2021YFF0604000) （2021YFF0604000）
呼吸疾病国家重点实验室/广州呼吸健康研究院/国家呼吸中心临床自主探索项目(SKLRHQN20205) （SKLRHQN20205）
广州市临床特色技术项目(2023C-TS10) （2023C-TS10）
